▶Vasant Narasimhan has led a significant strategic transformation at Novartis, shifting it from a diversified conglomerate to a 'pure-play innovative medicines company' by divesting assets like Alcon, Sandoz, and its Roche stake.Apr 2026
▶He views China as a critical and rapidly expanding pharmaceutical market, noting it is the world's second-largest, growing at a double-digit rate, and now leads the world in the speed of clinical trial recruitment.Apr 2026
▶Narasimhan positions Novartis at the forefront of advanced medical technologies, emphasizing its leadership in radioligand therapies, cell and gene therapies, and RNA therapeutics.Apr 2026
▶He consistently highlights the stagnation of the European pharmaceutical market, citing its shrinking size relative to the U.S. and policies that disincentivize growth and delay patient access to new drugs.Apr 2026
▶Narasimhan's assertion that 30-40% of new drugs are not launched in Europe, limiting patient access, presents a strong critique of the continent's regulatory and market environment that European policymakers might contest.Apr 2026
▶The claim that Italian government policy requires pharmaceutical companies to pay back revenue growth could be debated by officials regarding its specific implementation and impact on the broader business climate.Apr 2026
▶His warning that a 'balkanization' of clinical trials between the U.S. and China would be 'hugely damaging' for innovation represents a significant geopolitical concern, though the likelihood and severity of such a split could be viewed differently by policymakers in each country.Apr 2026
▶The decision to close all four Novartis manufacturing plants in the UK, while framed as a business decision, could be debated in terms of its impact on the UK's life sciences sector and supply chain resilience.Apr 2026
Not enough data for timeline
Sign up free to see the full intelligence report
Get started free